Nova Minerals Limited ("Nova" or the "Company") (NASDAQ: NVA) (ASX: NVA) (FRA: QM3)) is pleased to announce that preparations ...

Valvoline Global is set to make its partnership debut with FIFA's flagship tournament.The sponsorship reflects the rapid ...

KELOWNA, BC / ACCESS Newswire / May 30, 2025 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or the "Company"), a leading producer of innovative and award-winning cannabis products, hel ...

VANCOUVER, BC / ACCESS Newswire / May 30, 2025 / GLG Life Tech Corporation (TSX:GLG) ("GLG" or the "Company"), a global leader in the agricultural and commercial development of high-quality zero-calor ...

Zedcor Inc. (TSXV: ZDC) (the "Company" or "Zedcor") announces that on May 29, 2025, 2,935,000 Restricted Share Units (RSUs) were granted to employees ...

ANAHEIM, CA / ACCESS Newswire / May 30, 2025 / Phoenix Motor Inc. (OTC PINK:PEVM), a leading manufacturer of heavy-duty transit buses and electrification solutions provider for medium-duty vehicles, t ...

Very Polite Agency is pleased to announce it is a Gold Sponsor at the Centurion One Capital 6th Annual LA Summit held at the iconic Beverly ...

VANCOUVER, BC / ACCESS Newswire / May 30, 2025 / Metavista3D Inc. (TSXV:DDD)(FSE:E3T) ("Metavista3D" or the "Company") is providing this bi-weekly default status report in accordance with National Pol ...

SAN ANTONIO, TEXAS / ACCESS Newswire / May 30, 2025 / To keep the spotlight on women in global aviation and aerospace in recent months, Olga Custodio's release of her awe-inspiring memoir, Flightpath ...

Cancellation of 6,899,011 ordinary shares held in treasury by EQTThe cancellation was resolved by the Annual Shareholders' Meeting 2025As of 30 May 2025, there are 1,177,185,346 shares outstanding ...

NORTHAMPTON, MA / ACCESS Newswire / May 30, 2025 / Key PointsMarathon Petroleum Corporation set a company record for recognition at this year's American Fuel & Petrochemical Manufacturers safety ...

TURKU, FI / ACCESS Newswire / May 30, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Phase I study shows promising clinical activity and tolerability of bexmarilimab plus standard-of-care in hig ...